Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.
Launched by UNIVERSITY OF PENNSYLVANIA · Jul 2, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a special device called the Reletex Reliefband can help reduce nausea and vomiting after bariatric sleeve surgery, a type of weight-loss surgery. The Reliefband is a small, wearable device that uses gentle electrical pulses on the skin to help control nausea without using extra medicine. Researchers want to see if adding this device to the usual care can make patients feel better, reduce the need for nausea medicines, lower side effects like drowsiness, help patients get moving sooner, and speed up recovery after surgery.
Adults between 18 and 75 years old who are having robotic sleeve gastrectomy surgery and have a body mass index (BMI) of 35 or higher may be eligible to join. Participants will follow the hospital’s standard recovery plan and will wear the Reliefband for 24 hours after surgery. Nurses will regularly check how the device feels, monitor nausea, pain, and how much patients are moving around. Some people won’t be able to join, like those with certain medical devices (like pacemakers), pregnant women, smokers, or those with specific health conditions. This study will compare the Reliefband to a fake device (placebo) to see if it really helps reduce nausea and improve recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults 18-75 years of age BMI 35 or greater Patients eligible for and undergoing a Robotic Sleeve Gastrectomy - Due to the nature of the Robotic Sleeve Gastrectomy patients who may be unable to follow or comprehend the long-term restrictions and/or requirements inherent of the surgery due to altered mentation are excluded from having the surgery.
- • Able to consent on own behalf
- Exclusion Criteria:
- • A diagnosis of gastroparesis Pregnancy Presence of a cardiac pacemaker/defibrillator or intrathecal pump Current smoker or tobacco use within 30 days of procedure. Known allergic reactions to conductivity gel.
- • -
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Lisa Dobruskin, MD
Principal Investigator
Penn Medicine Princeton Medical Center for Bariatric Surgery and Metabolic Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported